Comparative Evaluation of Central Muscarinic Receptor Binding Activity by Oxybutynin, Tolterodine and Darifenacin Used to Treat Overactive Bladder

Journal of Urology

Volumn 177, Issue 2, 2007, Pages 766-770

  Oki, Tomomi ^a   Kageyama, Aiko ^a   Takagi, Yukiko ^a   Uchida, Shinya ^a   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

bladder; cerebral cortex; cholinergic antagonists; mice; muscarinic; receptors

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DRUG METABOLITE; METHYLSCOPOLAMINE; MUSCARINIC RECEPTOR; N DESETHYLOXYBUTYNIN; OXYBUTYNIN; TOLTERODINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EVALUATION; MALE; MOUSE; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; TISSUE HOMOGENATE; TREATMENT OUTCOME;

ANIMALS; BENZHYDRYL COMPOUNDS; BENZOFURANS; CEREBRAL CORTEX; CRESOLS; MALE; MANDELIC ACIDS; MICE; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PYRROLIDINES; RECEPTORS, MUSCARINIC; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 33845989147     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.09.079     Document Type: Article

References (20)

1. Yarker Y.E., Goa K.L., and Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6 (1995) 243
2. Nilvebrant L., Andersson K.-E., Gillberg P.G., Stahl M., and Sparf B. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 327 (1997) 195
3. 3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 13 (2004) 1493
4. Pakulski C., Drobnik L., and Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit 6 (2000) 314
5. Scheife R., and Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27 (2005) 144
6. Todorova A., Vonderheid-Guth B., and Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41 (2001) 636
7. Pahlman I., d'Argy R., and Nilvebrant L. Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. Arzneimittelforschung 51 (2001) 125
8. 3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 96 (2005) 1055
9. Kay G.G., Abou-Donia M.B., Messer Jr. W.S., Murphy D.G., Tsao J.W., and Ouslander J.G. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 53 (2005) 2195
10. Lipton R.B., Kolodner K., and Wesnes K. Assessment of cognitive function of the elderly population; effects of darifenacin. J Urol 173 (2005) 493
11. Parsons M., Robinson D., and Cardozo L. Darifenacin in the treatment of overactive bladder. Inter J Clin Prac 59 (2005) 831
12. Diokno A.C., Appell R.A., Sand P.K., Dmochowski R.R., Gburek B.M., Klimberg I.W., et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78 (2003) 687
13. 35S]GTPγS in rat brain and spinal cord. Br J Pharmacol 139 (2003) 1462
14. Douchamps J., Derenne F., Stockis A., Gangji D., Juvent M., and Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35 (1988) 515
15. Andersson S.H., Lindgren A., and Postlind H. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs. Drug Metab Dispos 26 (1998) 528
16. Sarter M., and Bruno J.P. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev 23 (1997) 28
17. Maruyama S., Oki T., Otsuka A., Shinbo H., Ozono S., Kageyama S., et al. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol 175 (2006) 365
18. Pietzko A., Dimpfel W., Schwantes U., and Topfmeier P. Influence of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 47 (1994) 337
19. Kay G.G., and Granville L.J. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 27 (2005) 127
20. Drachman D.A., and Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30 (1974) 113